Clinical Trial Update: Inhibiting Beta-adrenergic and COX-2 Signaling During the Perioperative Period to Reduce Ovarian Cancer Progression [Phase 2]

View source ↗

Summary

Phase 2 clinical trial investigating perioperative inhibition of beta-adrenergic and COX-2 signaling to reduce progression of ovarian cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer
• Ovarian Cancer Metastatic
• Ovarian Cancer Recurrent

Snippet

Sponsor: Tel-Aviv Sourasky Medical Center | Conditions: Ovarian Cancer, Ovarian Cancer Metastatic Recurrent | Phase 2 | Status: RECRUITING